Nordic Nanovector: Single-dose Betalutin® shows promising efficacy, improved duration of response and favourable safety in relapsed NHL patients
Updated results reported at the ASH Annual MeetingOslo, Norway, 5 December 2016 Nordic Nanovector ASA (OSE: NANO) presented yesterday the updated results from its ongoing Lymrit 37-01 Phase 1/2 clinical trial of Betalutin® (177Lu-satetraxetan-lilotomab) in subjects with relapsed non-Hodgkin lymphoma (NHL) at the 58th Annual American Society of Hematology (ASH) meeting (San Diego, CA, USA). This press release was previously issued on Sunday 4 December at 2:30am CET. A conference call will be held today at 11 am CET. Please see conference call details below. The updated data confirm